Erectile Dysfunction Clinical Trial
— ERECTION 2Official title:
The Impact of a Plant-based Meat Meal Versus an Animal Meat Meal on Erectile Function in Healthy Men.
NCT number | NCT06273592 |
Other study ID # | 2023-15558 |
Secondary ID | |
Status | Not yet recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2024 |
Est. completion date | June 2026 |
The goal of this study is to determine whether erectile function is differentially impacted by a single plant-based meat meal versus a single animal meat meal in healthy men with normal erectile function.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | June 2026 |
Est. primary completion date | June 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 32 Years |
Eligibility | Inclusion Criteria: - Subject provides written informed consent and HIPAA authorization in English before any study procedures are conducted. (If the subject is a fluent Spanish and/or other language speaker, subject must also be fluent in English (understanding and speaking) to be eligible for this study.) - IIEF score greater or equal to 22 - Subject is currently taking no medication other than prn MDIs No change in supplements if applicable - Subject will have had penile sexual intercourse (either vaginal or anal penetration) within 12 weeks of enrollment - Male (biological) aged 18-32 years old - Lives within commuting distance of Montefiore Health System - Subject's significant other (if applicable) agrees to support the subject during the study - Subject agrees to avoid all illicit drugs, NSAIDS, and alcohol for at least two days prior to Rigiscan™ recording and on the days and nights of Rigiscan™ recording - Subject agrees to refrain from sexual activity for at least 24 hours prior to Rigiscan™ placement and to have no sexual activity on the days and nights of Rigiscan™ recording - Subject agrees to not view, read, or otherwise consume erotic or pornographic material for at least 24 hours prior to the days and nights of Rigiscan™ recording and on the days and nights of Rigiscan™ recording - Subject agrees to not have an orgasm for 24 hours prior to both the days and nights of Rigiscan™ recording and on the days and nights of Rigiscan™ recording - Subject agrees to come to Montefiore to undergo Rigiscan™ training - Subject agrees to only consume/drink permitted food/beverages - Subject agrees to attend all in person visits at Montefiore and to undergo all blood draws and other testing - Subject agrees to not use mouthwash or mouth rinses or intentionally spit for the entire duration of the study. Subjects will be asked to refrain from using mouthwash for at least 2 days prior to enrollment - BMI <27, BMI >=18.5, weight >110 lbs - Subject agrees to comply with the study procedures and visits - Subject exercises for at least 15 minutes at least two times per week - If exercise is done, subjects will exercise for the same amount of time and at a similar intensity each day of Rigiscan™ testing. Otherwise, no exercise will be performed on Rigiscan™ days. - If enrolled, subjects agree to not modify their dietary habits throughout the duration of the study other than during the two evenings when food is provided. - If enrolled, subjects agree to fast when requested to fast Exclusion Criteria: - Relevant dietary allergy - Vegetarian or Vegan dietary pattern - History of an eating disorder and/or food addiction - Hypertension and or history of hypertension with or without medical treatment. Systolic blood pressure > 150mmHg and/or diastolic blood pressure >100mmHg on Visit one. Heart rate >99 on Visit one. Systolic blood pressure < 85mmHg and/or diastolic blood pressure < 50mmHg on Visit one. Heart rate < 35 on Visit one - BMI >=27, BMI <18.5, or weight <= 110lbs - Known chronic medical disease other than non-inflammatory musculoskeletal disease, asthma - Subjects who are taking benzodiazepines, stimulants (e.g. for ADHD), SSRI, anti-depressants and/or beta blockers - Obstructive sleep apnea (OSA) diagnosis or an ongoing evaluation for possible OSA - Score greater than 2 on the STOP-Bang OSA screening tool - Having the diagnosis of Restless Leg Syndrome - Having insomnia as defined by: Subject with insomnia would have difficulty initiating or maintaining sleep (30 minutes or more at sleep initiation or 30 minutes or more to fall back asleep if wakes during the night). The above occurs at least 3 times per week for at least 1 month. Furthermore, there must be adequate opportunity for sleep and there must be associated morbidity (feels tired during the day). Definition based on: The International Classification of Sleep Disorders - Third Edition (ICSD-3), 2014 - History of kidney disease or hyperkalemia - Subject has received an investigational drug within 30 days prior to signing consent - Erectile dysfunction - Has any condition (e.g., psychiatric illness) or situation that, in the investigator's opinion, may confound the study results, or may interfere significantly with the patient's ability to adhere with study procedures - Currently undergoing treatment for Peyronie's Disease - Abnormal Testosterone or Thyroid Stimulating Hormone level - Treated hypogonadism or hypothyroidism - Planned travel during the study - History of substance abuse in the last 12 months - Illicit drug use, smoking, or vaping within 4 weeks - Upper respiratory illness within two weeks on screening - If profession requires being on call, no overnight or on call duties during the study - Subject reports any communicable skin or venereal disease - Transgender status (Individuals who have undergone or are undergoing hormone replacement therapy or who have undergone gender affirming surgery. Individuals who plan to begin hormone replacement therapy or to undergo gender affirming surgery during the study.) - Subject reports rash or lesion on the penis or surrounding area |
Country | Name | City | State |
---|---|---|---|
United States | Montefiore Medical Center | Bronx | New York |
Lead Sponsor | Collaborator |
---|---|
Montefiore Medical Center | Beyond Meat |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Heart rate | Comparing heart rate by dietary pattern at both time points after overnight sleep after consuming the 1 meal and compared to its respective baseline in beats/minute. | Pre and post overnight Rigiscan recording. Up to 7 months. | |
Other | Blood pressure | Comparing blood pressure (both systolic and diastolic) by dietary pattern at both time points after overnight sleep after consuming the 1 meal and compared to its respective baseline in mmHg. | Pre and post overnight Rigiscan recording. Up to 7 months. | |
Primary | Percent of time with =70% erection during overnight sleep after 1 meal | Total time (in minutes) when penile rigidity is =70% at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). | During overnight sleep directly after consuming the 1 meal. Up to 7 months. | |
Secondary | Erection events per hour during overnight sleep after 1 meal | Total number of erection events lasting =5 minutes and with =70% rigidity at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). This result will be reported as Erection Events/hour. | During overnight sleep directly after consuming the 1 meal. Up to 7 months. | |
Secondary | Tumescence events per hour during overnight sleep after 1 meal. | Total number of tumescence events lasting =5 minutes and when penile circumference increases by =2cm at both the tip and the base of the penis compared to their respective baselines as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). This result will be reported as Tumescence events/hour. | During overnight sleep directly after consuming the 1 meal. Up to 7 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |